SYDNEY, AUSTRALIA: Anagenics Limited (AN1) has made a significant stride by announcing the acquisition of Face MediGroup (FMG), a prominent Australian professional skincare and beauty retailer.

This strategic move aligns seamlessly with AN1’s existing subsidiary, BLC Cosmetics (BLC), which operates with a B2B focus. The integration of FMG bolsters AN1’s presence across both retail and wholesale distribution networks within Australia and New Zealand’s professional beauty market.

The amalgamation of BLC and FMG is poised to invigorate revenue growth by merging physical and virtual consultation avenues, coupled with a diversified range of products:

• FMG, recognized for its accredited skincare offerings, operates both in the physical realm through its Face Mediskin retail store in Bella Vista and in the digital landscape through its digital platforms, facemediskin.com.au and prodermal.com.au. Leveraging BLC’s exclusive brand distribution arrangements, FMG aims to enhance its eCommerce and retail channels’ profitability.
• BLC’s online platform empowers certified beauty therapy professionals to access prescribed beauty products from accredited providers. BLC intends to expand its B2B professional channel, bolster its direct-to-consumer (D2C) and eCommerce capabilities, while also exploring potential avenues for physical retail expansion via FMG’s retail wing.

The co-founders of Face MediGroup, Matt and Sarah Perry, will officially join AN1, spearheading the leadership of the newly integrated beauty enterprise. Their participation will be cemented through AN1 scrip involvement.

The acquisition of Face MediGroup charts a trajectory toward profitable growth for AN1, enabling the firm to capitalize on its streamlined cost structure. With the FMG acquisition in place, AN1’s revenue is set to surge by 53%, driven by various high-growth revenue streams. This move not only unlocks potential for enhanced gross margins but also operational cost reductions, marked by improvements in IT, supply chain, and financial efficiencies.